Primary Care for People With Alcohol Use Disorder

Gregory A. Jaffe, MD, MSEd
Adam Visconti, MD, MPH
Kento Sonoda, MD, MPH

American Family Physician. 2026;114(4):358-365.

Author Disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

Alcohol use disorder is one of the most common chronic conditions encountered in primary care. In the United States, 1 in 10 people 12 years and older had alcohol use disorder in 2024. Patients with alcohol use disorder have increased risk for complications and comorbidities in gastrointestinal, cardiovascular, and neurologic systems, as well as anxiety and mood disorders, trauma-related stress disorders, suicide, and unintentional injuries. The US Preventive Services Task Force recommends screening adults with the abbreviated Alcohol Use Disorders Identification Test-Consumption or similar tool. Routine evaluation of patients with alcohol use disorder can include focused physical examination, blood tests, imaging studies to evaluate liver function and fibrosis, and assessment for the likelihood of developing alcohol withdrawal syndrome. Treatment in the primary care setting is effective, and all patients with alcohol use disorder should receive a brief behavioral counseling intervention and treatment or referral for treatment, if indicated. Treatment of co-occurring mental health conditions increases the likelihood of recovery from both conditions. Patients should receive routinely recommended vaccines, including the pneumococcal vaccine in those 19 years or older.

In the United States, 1 in 10 people 12 years and older (27.9 million people) had alcohol use disorder (AUD) in 2024.1 Prevalence of AUD, as well as associated deaths, has increased sharply in recent years, partially due to an increase in incidence during the COVID-19 pandemic.2 In addition to increased risk of liver and pancreatic disease, people with AUD and heavy alcohol consumption have higher morbidity and mortality from cardiovascular causes (eg, hypertension, cardiovascular disease, atrial fibrillation), neurologic conditions (eg, dementia), cancer, nutritional deficiencies, accidents, and suicide. Excess alcohol use is a leading cause of preventable death in the United States, behind tobacco, poor diet and physical inactivity, and illicit drugs.3

Although abstinence from alcohol is the safest approach for most people with AUD, harm reduction strategies that reduce heavy alcohol consumption are also effective. Primary care physicians should be aware of common issues that are caused by, or co-occur with, heavy alcohol use and be able to identify and treat these conditions appropriately.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating Comments
All adults, including those who are pregnant, should be screened for unhealthy alcohol use in the primary care setting; patients with at-risk or hazardous drinking should receive brief behavioral counseling interventions.4 B Systematic review and US Preventive Services Task Force B recommendation
Due to compounding risk factors for alcohol-associated liver dis- ease and certain types of cancers, people with AUD should avoid using combustible tobacco.21 A Systematic review and US Preventive Services Task Force A recommendation
Primary care physicians should screen for and treat co-occurring mental health conditions in people with AUD.36,37 A Systematic review, meta-analysis, and Cochrane review
People with AUD should be screened for other substance use disorders with the Drug Abuse Screening Test-10 or other validated tool.31,40,41 C Cohort studies; meta-analysis showing higher prevalence of other substance use disorders in people with AUD
People with AUD should be screened regularly for suicide risk.43,44 C Systematic review and meta-analysis with disease-oriented outcomes
People with AUD who are 19 years or older should receive pneumococcal vaccination with PCV 15 (Vaxneuvance), PCV 20 (Prevnar 20), or PCV 21 (Capvaxive).56 C Consensus guideline

AUD = alcohol use disorder; PCV = pneumococcal conjugate vaccine.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

GREGORY A. JAFFE, MD, MSEd, is an assistant professor in the Department of Family and Community Medicine at Thomas Jefferson University, Philadelphia, Pennsylvania.

ADAM VISCONTI, MD, MPH, is an assistant professor in the Department of Family Medicine at MedStar Georgetown University Hospital, Washington, District of Columbia.

KENTO SONODA, MD, MPH, AAHIVS, is an associate professor in the Department of Family and Community Medicine at Saint Louis University, St. Louis, Missouri, and an AFP contributing editor.

Address correspondence to Gregory A. Jaffe, MD, MSEd, at gregory.jaffe@jefferson.edu.

Author Disclosure: No relevant financial relationships.

  1. 1.National Institute on Alcohol Abuse and Alcoholism. Alcohol use disorder (AUD) in the United States: age groups and demographic characteristics. Updated August 2025. Accessed August 4, 2026. https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics​
  2. 2.Ayyala-Somayajula D, Dodge JL, Leventhal AM, et al. Trends in alcohol use after the COVID-19 pandemic: a national cross-sectional study. Ann Intern Med. 2025;178(1):139-142.
  3. 3.National Institute on Alcohol Abuse and Alcoholism. Alcohol-related emergencies and deaths in the United States. Updated March 2026. Accessed August 4, 2026. https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics-z/alcohol-facts-and-statistics/alcohol-related-emergencies-and-deaths-united-states​
  4. 4.Curry SJ, Krist AH, Owens DK, et al. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Prevention Services Task Force recommendation statement. JAMA. 2018;320(18):1899-1909.
  5. 5.Miller W, West J, Mills H. MillerWWestJMillsHScreening tools for unhealthy alcohol use [FPIN's Help Desk Answers]. Am Fam Physician2017; 96(11): online. Accessed October 27, 2025. https://www.aafp.org/afp/2017/1201/od2
  6. 6.National Institute on Alcohol Abuse and Alcoholism. Screen and assess. Updated May 8, 2025. Accessed October 13, 2025. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/screen-and-assess-use-quick-effective-methods​
  7. 7.Arnold MJ. Alcohol-associated liver disease: guidelines from the American College of Gastroenterology [Practice Guidelines]. Am Fam Physician. 2025;111(3):284-286.
  8. 8.Levy SJL, Williams JF; Committee on Substance Use and Prevention. Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016;138(1):e20161211.
  9. 9.National Institute on Alcohol Abuse and Alcoholism. Alcohol screening and brief intervention for youth: a practitioner's guide. Accessed February 2, 2026. https://www.niaaa.nih.gov/alcohols-effects-health/professional-education-materials/alcohol-screening-and-brief-intervention-youth-practitioners-guide/resources​
  10. 10.Diagnostic and Statistical Manual of Mental Disorders, 5th ed. American Psychiatric Association;2013:490–491.
  11. 11.Phillips AZ, Wang Y, Allen NB. Patterns of health care interactions of individuals with alcohol use disorder. J Subst Use Addict Treat. 2024;159:209251.
  12. 12.Tiglao SM, Meisenheimer ES, Oh RC. Alcohol withdrawal syndrome: outpatient management. Am Fam Physician. 2021;104(3):253-262.
  13. 13.National Institute on Alcohol Abuse and Alcoholism. Medical complications: common alcohol-related concerns. Updated May 8, 2025. Accessed October 13, 2025. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/medical-complications-common-alcohol-related-concerns​
  14. 14.Poorman E, McQuade BM, Messmer S. Medications for alcohol use disorder. Am Fam Physician. 2024;109(1):71-78.
  15. 15.World Health Organization. No level of alcohol consumption is safe for our health. January 4, 2023. Accessed February 4, 2026. https://www.who.int/europe/news/item/04-01-2023-no-level-of-alcohol-consumption-is-safe-for-our-health​
  16. 16.US Surgeon General. Alcohol and cancer risk. Accessed August 4, 2026. https://www.hhs.gov/sites/default/files/oash-alcohol-cancer-risk.pdf​
  17. 17.Jun S, Park H, Kim UJ, et al. The combined effects of alcohol consumption and smoking on cancer risk by exposure level. J Korean Med Sci. 2024;39(22):e185.
  18. 18.Kendrick S, Day C. Natural history and factors influencing the course of alcohol-related liver disease. Clin Liver Dis (Hoboken). 2013;2(2):61-63.
  19. 19.Jophlin LL, Singal AK, Bataller R, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024;119(1):30-54.
  20. 20.Ali H, Jahagirdar V, Blaney H, et al. Forecasting alcohol-related liver disease mortality trends in younger populations using advanced time-series models: a 1999–2030 analysis. JGH Open. 2024;8(12):e70057.
  21. 21.US Preventive Services Task Force. Tobacco smoking cessation in adults, including pregnant persons: interventions. January 19, 2021. Accessed September 7, 2025. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions​
  22. 22.Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases. Hepatology. 2020;71(1):306-333.
  23. 23.Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395-405.
  24. 24.Mahalingam S, Bellamkonda R, Arumugam MK, et al. Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease. Biochem Pharmacol. 2023;213:115613.
  25. 25.Biddinger KJ, Emdin CA, Haas ME, et al. Association of habitual alcohol intake with risk of cardiovascular disease. JAMA Netw Open. 2022;5(3):e223849.
  26. 26.Chopra K, Tiwari V. Alcoholic neuropathy. Br J Clin Pharmacol. 2012;73(3):348-362.
  27. 27.Miller J, Wells L, Nwulu U, et al. Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: a systematic review. Am J Clin Nutr. 2018;108(6):1196-1208.
  28. 28.Gramlich L, Tandon P, Rahman A, et al. Nutrition status in patients with sustained heavy alcohol use. Updated September 24, 2025. Accessed October 2, 2025. https://www.uptodate.com/contents/nutrition-status-in-patients-with-sustained-heavy-alcohol-use​
  29. 29.Singal AK, Charlton MR. Nutrition in alcoholic liver disease. Clin Liver Dis. 2012;16(4):805-826.
  30. 30.Suter M, Strik W, Moggi F. Depressive symptoms as a predictor of alcohol relapse after residential treatment programs for alcohol use disorder. J Subst Abuse Treat. 2011;41(3):225-232.
  31. 31.National Institute on Alcohol Abuse and Alcoholism. Mental health issues: alcohol use disorder and common co-occurring conditions. Updated May 8, 2025. Accessed October 13, 2025. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/mental-health-issues-alcohol-use-disorder-and-common-co-occurring-conditions​
  32. 32.National Institute of Mental Health. Mental illness. Updated September 2024. Accessed August 3, 2026. https://www.nimh.nih.gov/health/statistics/mental-illness​
  33. 33.Hunt GE, Malhi GS, Cleary M, et al. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990–2015: systematic review and meta-analysis. J Affect Disord. 2016;206:331-349.
  34. 34.Barbuti M, Maiello M, Spera V, et al. Challenges of treating ADHD with comorbid substance use disorder. J Clin Med. 2023;12(9):3096.
  35. 35.Castillo-Carniglia A, Keyes KM, Hasin DS, et al. Psychiatric comorbidities in alcohol use disorder. Lancet Psychiatry. 2019;6(12):1068-1080.
  36. 36.Agabio R, Trogu E, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev. 2018(4):CD008581.
  37. 37.Riper H, Andersson G, Hunter SB, et al. Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing. Addiction. 2014;109(3):394-406.
  38. 38.Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder. JAMA Psychiatry. 2015;72(8):757-766.
  39. 39.Castle IJP, Dong C, Haughwout SP, et al. Emergency department visits for adverse drug reactions involving alcohol: United States, 2005 to 2011. Alcohol Clin Exp Res. 2016;40(9):1913-1925.
  40. 40.Stephenson M, Aggen SH, Polak K, et al. Patterns and correlates of polysubstance use among individuals with severe alcohol use disorder. Alcohol Alcohol. 2022;57(5):622-629.
  41. 41.Pompili M, Serafini G, Innamorati M, et al. Suicidal behavior and alcohol abuse. Int J Environ Res Public Health. 2010;7(4):1392-1431.
  42. 42.Berger JT, Rosner F, Kark P; Committee on Bioethical Issues of the Medical Society of the State of New York. Reporting by physicians of impaired drivers and potentially impaired drivers. J Gen Intern Med. 2000;15(9):667-672.
  43. 43.Amiri S, Behnezhad S. Alcohol use and risk of suicide: a systematic review and meta-analysis. J Addict Dis. 2020;38(2):200-213.
  44. 44.Krystkiewicz M, Soyka M. Suicide risk in alcohol use disorders. Healthcare (Basel). 2025;13(5):535.
  45. 45.Angerhofer Richards J, Cruz M, Stewart C, et al. Effectiveness of integrating suicide care in primary care. Ann Intern Med. 2024;177(11):1471-1481.
  46. 46.Ebell MH. Identifying patients at risk for suicidal ideation or behaviors [Point of Care Guide]. Am Fam Physician. 2023;108(3):311-312.
  47. 47.Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657-1669.
  48. 48.Serra-Burriel M, Graupera I, Torán P; investigators of the LiverScreen Consortium. Transient elastography for screening of liver fibrosis. J Hepatol. 2019;71(6):1141-1151.
  49. 49.Asphaug L, Thiele M, Krag A, et al. Cost-effectiveness of noninvasive screening for alcohol-related liver fibrosis. Hepatology. 2020;71(6):2093-2104.
  50. 50.US Centers for Disease Control and Prevention. Clinical testing and diagnosis for tuberculosis. April 17, 2025. Accessed September 9, 2025. https://www.cdc.gov/tb/hcp/testing-diagnosis/index.html​
  51. 51.Owens DK, Davidson KW, Krist AH, et al. Screening for HIV infection. JAMA. 2019;321(23):2326-2336.
  52. 52.US Preventive Services Task Force. Oral cancer. November 15, 2013. Accessed September 7, 2025. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/oral-cancer-screening​
  53. 53.Lingen MW, Abt E, Agrawal N, et al. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity. J Am Dent Assoc. 2017;148(10):712-727.e10.
  54. 54.Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer. JAMA. 2024;331(22):1918-1930.
  55. 55.Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer. JAMA. 2021;325(19):1965-1977.
  56. 56.US Centers for Disease Control and Prevention. Adult immunization schedule by medical condition and other indication. Updated July 2, 2025. Accessed August 4, 2026. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html​
  57. 57.Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States. MMWR Recomm Rep. 2020;69(5):1-38.
  58. 58.Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19–59 years. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483.
  59. 59.Dejong K, Olyaei A, Lo JO. Alcohol use in pregnancy. Clin Obstet Gynecol. 2019;62(1):142-155.
  60. 60.Dawson DA, Li TK, Grant BF. A prospective study of risk drinking: at risk for what? Drug Alcohol Depend. 2008;95(1):62-72.
  61. 61.Salisbury-Afshar E, Fleming M. Identification of and treatment for unhealthy alcohol use in primary care settings [editorial]. Am Fam Physician. 2019;99(12):733-734.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.